GSK To Buy T Cell-engager For Multiple Myeloma From Chimagen Biosciences For Up To $750 Mln

GSK agreed to acquire from private clinical-stage biotech Chimagen Biosciences a potential best-in-class trispecific T-cell engager for multiple myeloma. The transaction expands GSK's oncology pipeline, though the provided article text does not disclose financial terms, development-stage details, or expected closing timing.